TY  - JOUR
AU  - Leiva, Maria Carmen
AU  - Ortiz, Raul
AU  - Contreras-Caceres, Rafael
AU  - Perazzoli, Gloria
AU  - Mayevych, Iryna
AU  - Lopez-Romero, Juan Manuel
AU  - Sarabia, Francisco
AU  - Baeyens, Jose Manuel
AU  - Melguizo, Consolación
AU  - Prados, Jose
PY  - 2017
DO  - 10.1038/s41598-017-13816-z
UR  - http://hdl.handle.net/10668/11693
T2  - Scientific reports
AB  - Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid...
LA  - en
PB  - Nature Publishing Group
KW  - Molecular medicine
KW  - Oncology
KW  - Antineoplastic Agents
KW  - Breast Neoplasms
KW  - Cell Line
KW  - Female
KW  - Humans
KW  - Lignans
KW  - Lung Neoplasms
KW  - MCF-7 Cells
KW  - Nanoparticles
KW  - Neoplastic Stem Cells
KW  - Paclitaxel
KW  - Polyethylene Glycols
KW  - Spheroids, Cellular
KW  - Triglycerides
KW  - Tumor Cells, Cultured
KW  - beta-Cyclodextrins
TI  - Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.
TY  - research article
VL  - 7
ER  -